Keyphrases
Gallbladder
73%
Glucagon-like
72%
Colesevelam
69%
Cholecystokinin
57%
Glucose-lowering Drugs
49%
Type 2 Diabetes Mellitus (T2DM)
49%
Placebo
49%
Gallbladder Motility
48%
Fibroblast Growth Factor 19 (FGF19)
45%
Type 2 Diabetic Patients
42%
Bile Acid Sequestrants
38%
Gut Hormones
38%
Bile Acids
37%
Bigorexia
34%
Bile Acid Receptor
34%
Sevelamer
34%
Acute Effects
34%
Organic Anion Transporter
34%
Intestine
34%
Gut Axis
34%
Glucagon-like peptide-1 (GLP-1)
34%
Postprandial Response
34%
Bile Acid Transporters
34%
Liraglutide
34%
Type 2 Diabetes Prevention
34%
Healthy Individuals
34%
Gallbladder Contraction
34%
Bile
34%
Metabolic Consequences
34%
Cholecystectomy
34%
Type I Diabetes
34%
Type 1 Diabetes Mellitus (T1DM)
34%
Obstructive Sleep Apnea
34%
Hypercalcemia
34%
Paraffin Oil
34%
Farnesoid X Receptor
33%
Apical Sodium-dependent Bile Acid Transporter
29%
Oil Injection
26%
Exendin (9-39)
24%
Treatment Duration
17%
Healthy Controls
17%
Severe Hypercalcemia
17%
First Dose
15%
Hemoglobin A1c (HbA1c)
14%
Cell Sensitivity
13%
B Cells
13%
Meal Tolerance Test
11%
Intestinal Tract
11%
Expression Pattern
11%
FGF Receptor
11%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Bile Acid
76%
Colesevelam
69%
Placebo
67%
Cholecystokinin
57%
Glucagon-Like Peptide-1
52%
Glucagon Like Peptide 2
50%
Gastrointestinal Hormone
38%
Bile Acid Sequestrant
38%
Liraglutide
34%
Insulin Dependent Diabetes Mellitus
34%
Sevelamer
34%
Sleep Disordered Breathing
34%
Hypercalcaemia
34%
Liquid Paraffin
34%
Fibroblast Growth Factor 19
34%
Farnesoid X Receptor
25%
Exendin 9
24%
Hemoglobin A1c
19%
Disease
16%
G Protein Coupled Receptor
13%
Low Density Lipoprotein
9%
Monotherapy
9%
Vitamin D
8%
Disease Course
8%
Sodium Chloride
8%
Kidney Failure
8%
Granuloma
8%
Sun Exposure
8%
Prednisolone
8%
Antidiabetic Agent
8%
Receptor Antagonist
7%
Glucagon-Like Peptide 1 Receptor
7%
Cell Nucleus Receptor
6%
Cholelithiasis
6%
Metabolic Disorder
6%
Liver Disease
6%
Metabolic Syndrome X
6%
Cholecystitis
6%
Membrane Receptor
6%
Guanine Nucleotide Binding Protein
6%
Emulsifying Agent
6%
Fibroblast Growth Factor Receptor 4
5%
Receptor
5%
Medicine and Dentistry
Placebo
62%
Cholecystokinin
57%
Glucagon Like Peptide 1
52%
Glucagon Like Peptide 2
50%
Gallbladder Motility
49%
Gastrointestinal Hormone
38%
Bile Acid Sequestrant
38%
Liraglutide
34%
Sevelamer
34%
Gallbladder Contraction
34%
Patient with Type 1 Diabetes
34%
Obstructive Sleep Apnea
34%
Colesevelam
34%
Maturity Onset Diabetes of the Young
27%
Exendin 9
24%
Fibroblast Growth Factor 19
22%
Body Mass Index
17%
Beta Cell
17%
Infusion
16%
Secretion (Process)
14%
Single Drug Dose
13%
Test Meal
11%
Insulin Sensitivity
8%
Sodium Chloride
8%
Glycemic Control
7%
Receptor Antagonist
7%
Glucagon Like Peptide 1 Receptor
7%
Disease
7%
Gallbladder Emptying
7%
Echography
7%
Bile Acid
6%
